Marketing

Mar 01, 2013
Pharmaceutical Executive
What can happen when reps focus on the physician-patient conversation? Al Topin reports.
Jan 01, 2013
Pharmaceutical Executive
Doctor-patient conversations aren't always what we think—this basic interaction represents both a problem and an opportunity for today's drug marketers, writes Al Topin.
Dec 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
How to stop worrying and learn to love the data.
Nov 01, 2012
Pharmaceutical Executive
How an agency and client behave after they split speaks volumes about their culture and character, writes Al Topin.
Oct 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
With respect to targeting, positioning, and launching new drugs, the ACA reform stands for Adjust, Change, and Adapt.
Sep 01, 2012
Pharmaceutical Executive
"Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets."
Sep 01, 2012
Pharmaceutical Executive
In the digital age, physicians don't call the shots when it comes to healthcare guidance, writes Al Topin.
Jul 01, 2012
Pharmaceutical Executive
At its core, pharma marketing is about conversations. Dynamic, persuasive conversations between companies and healthcare stakeholders. But one time it was simple; now it's not, writes Al Topin.
Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
Understanding the differences between drug and device marketing can make or break the brand's promotional activities.
Jun 01, 2012
Pharmaceutical Executive
By Pharmaceutical Executive Editors
New drug indications can be a brand manager's worst nightmare or a dream come true. The difference lies in the perspective and in the branding strategy.
native1_300x100
read more

farm-pump-ua.com/gormon-rosta.html
lorem ipsum